124 related articles for article (PubMed ID: 38042098)
21. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase plasminogen activator receptor (suPAR) promotes atherosclerosis.
Drueke TB; Massy ZA
Kidney Int; 2023 Mar; 103(3):451-454. PubMed ID: 36549362
[No Abstract] [Full Text] [Related]
23. Urokinase-type plasminogen activator soluble receptor (suPAR) assay in clinical routine: evaluation one year after its introduction in the high automation corelab of the A. Gemelli hospital.
Sarlo F; Urbani A; Baroni S
Clin Chem Lab Med; 2023 Jan; 61(2):e33-e35. PubMed ID: 36283064
[No Abstract] [Full Text] [Related]
24. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
25. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
26. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.
Higazi AA; Mazar A; Wang J; Reilly R; Henkin J; Kniss D; Cines D
Blood; 1996 May; 87(9):3545-9. PubMed ID: 8611676
[TBL] [Abstract][Full Text] [Related]
27. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
[TBL] [Abstract][Full Text] [Related]
28. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
29. Effect of recombinant-tissue plasminogen activator, low molecular weight urokinase and unfractionated heparin on platelet aggregation.
Paolini R; Casonato A; Boeri G; Luzzatto G; Girolami A; Sasahara AA; Cella G
J Med; 1993; 24(2-3):113-30. PubMed ID: 8409776
[TBL] [Abstract][Full Text] [Related]
30. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a novel inhibitor against urokinase-type plasminogen activator, a potential enzyme with a role in atherosclerotic plaque instability.
Ganguly R; Mylliemngap BJ; Bhattacharjee A
J Biomol Struct Dyn; 2023 May; 41(8):3485-3495. PubMed ID: 35362361
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor.
Higazi A; Cohen RL; Henkin J; Kniss D; Schwartz BS; Cines DB
J Biol Chem; 1995 Jul; 270(29):17375-80. PubMed ID: 7615542
[TBL] [Abstract][Full Text] [Related]
33. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Albo D; Rothman VL; Roberts DD; Tuszynski GP
Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
[TBL] [Abstract][Full Text] [Related]
34. [The analysis of plasma Urokinase-type plasminogen activator and Urokinase-type plasminogen activator receptor which unknown factor nosebleed patients].
Zhan L; Huang G; Wen W; Zhou Y; Tang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Nov; 21(22):1029-30, 1050. PubMed ID: 18257282
[TBL] [Abstract][Full Text] [Related]
35. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
36. [Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta].
Solomatina MA; Plekhanova OS; Il'inskaia OP; Kalinina NI; Mikhaĭlova EV; Tsokolaeva ZI; Tararak EM; Naumov VG; Parfenova EV
Tsitologiia; 2004; 46(4):352-60. PubMed ID: 15346794
[TBL] [Abstract][Full Text] [Related]
37. Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.
Rasmussen LJH; Ladelund S; Haupt TH; Ellekilde GE; Eugen-Olsen J; Andersen O
Crit Care Med; 2018 Dec; 46(12):1961-1968. PubMed ID: 30247244
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
Reuning U; Bang NU
Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
[TBL] [Abstract][Full Text] [Related]
39. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
Marschall C; Lengyel E; Nobutoh T; Braungart E; Douwes K; Simon A; Magdolen V; Reuning U; Degitz K
J Invest Dermatol; 1999 Jul; 113(1):69-76. PubMed ID: 10417621
[TBL] [Abstract][Full Text] [Related]
40. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor.
Masucci MT; Pedersen N; Blasi F
J Biol Chem; 1991 May; 266(14):8655-8. PubMed ID: 1851152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
